Literature DB >> 15546391

Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4.

Wendy T Watford1, Bruce D Hissong, Jay H Bream, Yuka Kanno, Linda Muul, John J O'Shea.   

Abstract

Produced in response to a variety of pathogenic organisms, interleukin (IL)-12 and IL-23 are key immunoregulatory cytokines that coordinate innate and adaptive immune responses. These dimeric cytokines share a subunit, designated p40, and bind to a common receptor chain, IL-12R beta 1. The receptor for IL-12 is composed of IL-12R beta 1 and IL-12R beta 2, whereas IL-23 binds to a receptor composed of IL-12R beta 1 and IL-23R. Both cytokines activate the Janus kinases Tyk2 and Jak2, the transcription factor signal transducer and activator of transcription 4 (STAT4), as well as other STATs. A major action of IL-12 is to promote the differentiation of naive CD4+ T cells into T-helper (Th) 1 cells, which produce interferon (IFN)-gamma, and deficiency of IL-12, IL-12R subunits or STAT4 is similar in many respects. In contrast, IL-23 promotes end-stage inflammation. Targeting IL-12, IL-23, and their downstream signaling elements would therefore be logical strategies for the treatment of immune-mediated diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546391     DOI: 10.1111/j.0105-2896.2004.00211.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  192 in total

Review 1.  Unraveling the genetic component of systemic sclerosis.

Authors:  José Ezequiel Martín; Lara Bossini-Castillo; Javier Martín
Journal:  Hum Genet       Date:  2012-01-05       Impact factor: 4.132

2.  Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis.

Authors:  Paula S Ramos; Elisabeth E Brown; Robert P Kimberly; Carl D Langefeld
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

3.  A novel class of anti-IL-12p40 antibodies: potent neutralization via inhibition of IL-12-IL-12Rβ2 and IL-23-IL-23R.

Authors:  Adam W Clarke; Lynn Poulton; Hoi Yi Wai; Stuart A Walker; Shanti David Victor; Teresa Domagala; Dragana Mraovic; Danyal Butt; Nina Shewmaker; Philip Jennings; Anthony G Doyle
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

4.  The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells.

Authors:  Hong-Sheng Dai; Nathaniel Griffin; Chelsea Bolyard; Hsiaoyin Charlene Mao; Jianying Zhang; Timothy P Cripe; Tadahiro Suenaga; Hisashi Arase; Ichiro Nakano; E A Chiocca; Balveen Kaur; Jianhua Yu; Michael A Caligiuri
Journal:  Immunity       Date:  2017-07-18       Impact factor: 31.745

5.  STAT4 deficiency reduces the development of atherosclerosis in mice.

Authors:  Parésa L Taghavie-Moghadam; Breanne N Gjurich; Rukhsana Jabeen; Purna Krishnamurthy; Mark H Kaplan; Anca D Dobrian; Jerry L Nadler; Elena V Galkina
Journal:  Atherosclerosis       Date:  2015-09-04       Impact factor: 5.162

6.  IL-12 Signals through the TCR To Support CD8 Innate Immune Responses.

Authors:  Nicholas P Goplen; Vikas Saxena; Karin M Knudson; Adam G Schrum; Diana Gil; Mark A Daniels; Rose Zamoyska; Emma Teixeiro
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

7.  Adhesion- and Degranulation-Promoting Adapter Protein Promotes CD8 T Cell Differentiation and Resident Memory Formation and Function during an Acute Infection.

Authors:  Jessica K Fiege; Lalit K Beura; Brandon J Burbach; Yoji Shimizu
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

Review 8.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.